Avvio Medical

Executive Summary

Avvio Medical is a clinical-stage medical device company pioneering a novel office-based treatment for kidney stones. Its proprietary technology combines low-pressure ultrasound with calcium-seeking microbubbles to fragment stones without general anesthesia or stents. This approach aims to shift the standard of care from hospital-based procedures to a safer, faster, and more accessible office setting, reducing costs and improving patient experience. The company is currently in Phase 1 clinical development, targeting a large and underserved market with significant unmet need. If successful, Avvio’s platform could disrupt the existing lithotripsy and ureteroscopy market, offering a non-invasive alternative that eliminates the need for operating room resources and anesthesia. The company has completed initial feasibility studies and is progressing toward pivotal trials. With a clear regulatory pathway and a strong intellectual property position, Avvio Medical represents a compelling early-stage investment opportunity in the urology device space.

Upcoming Catalysts (preview)

• Q3 2026Completion of Phase 1 Clinical Trial80% success
• Q1 2027FDA IDE Approval for Pivotal Trial65% success
• 2026Strategic Partnership or Licensing Deal40% success